• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agency of Health Technology Assessment of Uruguay
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canada’s Drug Agency (CDA-AMC)
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Healthcare Quality Institute
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Regione Emilia Romagna
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      The Swedish Council on Health Technology Assessment (SBU)
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [25417 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2025     NIHR Health Services and Delivery Research programme Evidence of the impact on and views of NHS staff following a colleague’s suicide to inform postvention guidance: a multi-methods study
2025     Agency for Care Effectiveness (ACE) Momelotinib for treating myelofibrosis in patients with moderate to severe anaemia
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Repotrectinib (solid tumours with neurotrophic tyrosine receptor kinase [NTRK] gene fusion) – Benefit assessment according to §35a Social Code Book V]
2025     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of technologies for the assessment of attention deficit hyperactivity disorder: a systematic review and economic model
2025     Agency for Care Effectiveness (ACE) Toripalimab for first-line systemic treatment of recurrent or metastatic nasopharyngeal carcinoma
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Repotrectinib (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2025     Haute Autorite de sante (HAS) [Next generation sequencing gene panel using circulating tumor DNA for medical lung cancer care]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elosulfase alfa (mucopolysaccharidosis IVA) – Benefit assessment according to §35a Social Code Book V]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [External beam radiotherapy delivered by ultra-hypofractionation for the treatment of prostate cancer]
2025     National Institute for Health and Care Excellence (NICE) Compression products for treating venous leg ulcers: late-stage assessment. NICE HealthTech guidance 758
2026     Agency for Care Effectiveness (ACE) Donanemab and lecanemab for treating mild cognitive impairment and mild dementia due to Alzheimer's disease
2026     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [The role of occupational exposures in the development of cancer among firefighters]
2026     Scottish Health Technologies Group (SHTG) National framework for evaluating the role of Surgical Care Practitioners (SCPs) in Scotland
2026     Agency for Care Effectiveness (ACE) Talquetamab for relapsed or refractory multiple myeloma
2026     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Assessment tools for identifying individuals exposed to prostitution, human trafficking for sexual purposes, and sexual exploitation through the dissemination of images or videos]
2026     Canada’s Drug Agency (CDA-AMC) Antiviral drugs for post-exposure prophylaxis against influenza A or influenza B
2026     Agency for Care Effectiveness (ACE) Inavolisib in combination with palbociclib and fulvestrant for PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer
2026     Canada’s Drug Agency (CDA-AMC) Cost-effectiveness of antiviral drugs to prevent or treat influenza A, influenza B, or zoonotic influenza
2026     Agency for Care Effectiveness (ACE) Ribociclib for the adjuvant treatment of HR-positive, HER2-negative stage II and III early breast cancer at high risk of recurrence
2026     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Diagnostic accuracy of different index-tests in diagnosing food allergy]
2026     Agency for Care Effectiveness (ACE) Capivasertib in combination with fulvestrant for HR-positive, HER2-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alteration
2026     Health Information and Quality Authority (HIQA) A systematic review on the association between alcohol consumption and mental health outcomes
2026     Agency for Care Effectiveness (ACE) Zolbetuximab for untreated HER2-negative, claudin-18.2-positive, unresectable advanced gastric or gastroesophageal junction adenocarcinoma
2026     Canada’s Drug Agency (CDA-AMC) Botulinum toxin A product comparison for upper limb spasticity, lower limb spasticity, and cervical dystonia
2026     Health Technology Wales (HTW) Cone-beam computed tomography for breast imaging in people with suspected breast cancer
2026     Canada’s Drug Agency (CDA-AMC) Ferric derisomaltose for heart failure and iron deficiency
2026     National Institute for Health and Care Excellence (NICE) Balloon cryoablation for Barrett's oesophagus. NICE HealthTech guidance 767
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Methods for evaluating digital technologies in health and social services]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [AI-based speech transcription software in health and social services: considerations for large-scale deployment]
2026     NIHR Health Services and Delivery Research programme Family Group Conferences as an alternative to Initial Child Protection Conferences for families on the Child Protection pathway: synopsis
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Application of the INESSS framework : assessing the value of digital technologies in health and social services]
2026     NIHR Health Technology Assessment programme Effectiveness of non-pharmacological interventions for fatigue in adults with long-term conditions: a synopsis of the EIFFEL mixed-methods evidence synthesis
2026     NIHR Health Technology Assessment programme Digital front door technologies to pre-assess people before assessment for NHS Talking Therapies [HTE10055]: early value assessment
2026     NIHR Health Technology Assessment programme The impact and cost-effectiveness of scaling up HCV treatment for achieving elimination among people who inject drugs in England: a synopsis including evidence synthesis and economic modelling
2026     National Institute for Health and Care Excellence (NICE) Digital technologies for applying algorithms to spirometry to support asthma and COPD diagnosis in primary care and community diagnostic centres: early-use assessment. NICE HealthTech guidance 776
2026     NIHR Health Technology Assessment programme Placental growth factor (PLGF)-based testing to help diagnose suspected pre-eclampsia: a systematic review and economic evaluation
2026     NIHR Health Technology Assessment programme Digitally enabled therapy for chronic tic disorders and Tourette Syndrome: a systematic review and economic evaluation
2026     National Institute for Health and Care Excellence (NICE) Transvenous embolisation for spontaneous intracranial hypotension caused by a cerebrospinal fluid–venous fistula. NICE HealthTech guidance 777
2026     Health Information and Quality Authority (HIQA) Modelling alcohol mortality risks and hospital admission rates-current-low
2026     NIHR Health Technology Assessment programme Roux-en-Y gastric bypass, adjustable gastric banding or sleeve gastrectomy for severe obesity: the By-Band-Sleeve randomised controlled trial
2026     National Institute for Health and Care Excellence (NICE) Belantamab mafodotin with bortezomib and dexamethasone for previously treated multiple myeloma. NICE technology appraisal guidance 1149
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Tumor biomarkers related to the management of advanced neuroendocrine tumors]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Symptoms and anxiety disorders in teenagers aged 12 to 17: identification, assessment and diagnostic processes, treatments, transitions in care and services]
2026     National Institute for Health and Care Excellence (NICE) Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over. NICE technology appraisal guidance 1147
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Single-port endoluminal robotic system for endoscopic submucosal dissection in patients with superficial colorectal lesions]
2026     National Institute for Health and Care Excellence (NICE) Sodium zirconium cyclosilicate for treating hyperkalaemia. NICE technology appraisal guidance 1148
2026     NIHR Health Technology Assessment programme Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Revision of the information materials on colorectal cancer screening]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Management of incidental imaging findings – pancreas]
2026     National Institute for Health and Care Excellence (NICE) Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors. NICE technology appraisal guidance 1146
2026     NIHR Health Services and Delivery Research programme A realist synthesis of integrated palliative care and oncology: synopsis
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Repetitive transcranial magnetic stimulation for treatment-resistant depression in adults: effectiveness, safety and efficiency]
2026     National Institute for Health and Care Excellence (NICE) Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma. NICE technology appraisal guidance 1145
2026     Health Information and Quality Authority (HIQA) Protocol for a health technology assessment of COVID-19 vaccination in Ireland
2026     NIHR Health Technology Assessment programme Effectiveness of psychosocial interventions for adults with substance use disorder that have a co-occurring mental health disorder: an umbrella review and illustrative cost-effectiveness analysis
2026     Basque Office for Health Technology Assessment (OSTEBA) [Active piezoelectric bone conduction hearing implant]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Drug costs – tracking trends in drug spending in Quebec from 2020 to 2025]
2026     National Institute for Health and Care Excellence (NICE) Subcutaneous spesolimab 1-ml formulation for preventing generalised pustular psoriasis flares in people 12 years and over (terminated appraisal). NICE technology appraisal guidance 1144
2026     Basque Office for Health Technology Assessment (OSTEBA) [Safety and efficacy of mandibular advancement devices in the management of obstructive sleep apnea]
2026     NIHR Health Technology Assessment programme Plain balloon angioplasty +/- bare metal stenting versus drug-coated balloon angioplasty +/- bare metal stenting versus primary drug-eluting stenting in patients with chronic limb-threatening ischaemia: BASIL-3, an open-label, three-arm, randomised, multi-centre, phase 3 trial
2026     Basque Office for Health Technology Assessment (OSTEBA) [Home self-management of oral anticoagulation therapy with vitamin K antagonists: evaluation of acceptability and cost-effectiveness]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Family medicine group: key figures, provincial review 2023-2024]
2026     Basque Office for Health Technology Assessment (OSTEBA) [High-intensity focused ultrasound for essential tremor and Parkinson’s disease]
2026     National Institute for Health and Care Excellence (NICE) Atogepant for treating migraine. NICE technology appraisal guidance 1172
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Appropriate use of laboratory tests – (1-3)-β-D-glucan serum testing]
2026     National Institute for Health and Care Excellence (NICE) Mirvetuximab soravtansine for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer. NICE technology appraisal guidance 1169
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Portrait of prehospital trauma triage in Québec (2013-2023) - Evaluation of the implementation of the Québec prehospital trauma triage scale (EQTPT)]
2026     National Institute for Health and Care Excellence (NICE) Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable. NICE technology appraisal guidance 1170
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Care and services models for youth with serious behavioural disorders and mental health issues]
2026     National Institute for Health and Care Excellence (NICE) Seladelpar for previously treated primary biliary cholangitis. NICE technology appraisal guidance 1171
2026     National Institute for Health and Care Excellence (NICE) Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer. NICE technology appraisal guidance 1167
2026     NIHR Health Technology Assessment programme A pragmatic, multicentre, placebo-controlled, 3-arm, double-blinded, randomised controlled trial, incorporating an internal pilot, to determine the role of bronchodilators in preventing exacerbations of bronchiectasis
2026     National Institute for Health and Care Excellence (NICE) Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy (terminated evaluation). NICE technology appraisal guidance 1168
2026     NIHR Health Technology Assessment programme Establishing the safety of waterbirth for mothers and their babies: the POOL cohort study with nested qualitative component
2026     National Institute for Health and Care Excellence (NICE) Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils. NICE technology appraisal guidance 1166
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Newborn screening for metachromatic leukodystrophy]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between quantity of services and quality of treatment outcome in corrective surgery of Hirschsprung's disease]
2026     NIHR Health Technology Assessment programme Gabapentin as an adjunct to multimodal pain regimens in surgical patients: the GAP placebo-controlled RCT and economic evaluation
2026     National Institute for Health and Care Excellence (NICE) Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer. NICE technology appraisal guidance 1165
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acupuncture for migraine prophylaxis]
2026     NIHR Health Technology Assessment programme Artificial Intelligence technologies for assessing skin lesions for referral on the urgent suspected cancer pathway to detect benign lesions and reduce secondary care specialist appointments: early value assessment
2026     National Institute for Health and Care Excellence (NICE) Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment. NICE technology appraisal guidance 1164
2026     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Efficacy and safety of emotional freedom techniques for the treatment of anxiety, depression and post traumatic stress disorders]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Review of the lower age limit and frequency of early-detection colonoscopy in the colorectal cancer screening programme]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Drug interventions following obesity surgery: Evidence report for the S3 guideline on the diagnosis and treatment of eating disorders]
2026     NIHR Health Technology Assessment programme Outcome after Selective early treatment for Closure of patent ductus ARteriosus in preterm babies, a multicentre, masked, randomised placebo-controlled parallel group trial (Baby-OSCAR trial)
2026     National Institute for Health and Care Excellence (NICE) Nusinersen and risdiplam for treating spinal muscular atrophy. NICE technology appraisal guidance 1162
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Psychological interventions following obesity surgery: Evidence report for the S3 guideline on the diagnosis and treatment of eating disorders]
2026     NIHR Health Technology Assessment programme Azithromycin therapy for prevention of chronic lung disease of prematurity (AZTEC): a randomised placebo-controlled trial
2026     National Institute for Health and Care Excellence (NICE) Nogapendekin alfa inbakicept with BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG (terminated evaluation). NICE technology appraisal guidance 1163
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Drug interventions for ARFID: Evidence report for the S3 guideline on the diagnosis and treatment of eating disorders]
2026     NIHR Health Technology Assessment programme Conservative versus liberal oxygenation targets in critically ill children: the Oxy-PICU RCT
2026     National Institute for Health and Care Excellence (NICE) Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic treatment. NICE technology appraisal guidance 1159
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Psychological interventions for ARFID: Evidence report for the S3 guideline on the diagnosis and treatment of eating disorders]
2026     NIHR Health Technology Assessment programme The clinical and cost-effectiveness of paravertebral blockade versus thoracic epidural blockade in reducing chronic post-thoracotomy pain: TOPIC2 RCT synopsis
2026     National Institute for Health and Care Excellence (NICE) Durvalumab with chemotherapy for neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinoma. NICE technology appraisal guidance 1160
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Local hyperbaric oxygen therapy for diabetic foot ulcers]
2026     NIHR Health Technology Assessment programme The clinical and cost-effectiveness of improving sleep via carer delivered strategies in people with dementia: the DREAMS START parallel multi-centre RCT
2026     National Institute for Health and Care Excellence (NICE) Sotatercept for treating pulmonary arterial hypertension. NICE technology appraisal guidance 1161
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [CR neuromodulation: Evidence report for the S3 guideline on chronic tinnitus]